Supernus Pharma (SUPN) Tops Q2 EPS by 23c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. NOW
2. GOOGL
3. MSFT
4. FTNT
5. EBAY
6. TENB
7. BIIB
8. CMG
9. KLAC
10. ETSY

Go back to Supernus Pharma (SUPN) Tops Q2 EPS by 23c

Supernus Announces Second Quarter 2021 Financial Results

August 4, 2021 4:10 PM EDT

Second quarter 2021 total revenues of $141.3 million, a 12% increase compared to 2020Qelbree launched in the U.S. for pediatric ADHD at the end of May 2021Qelbree sNDA for adult ADHD submitted to the FDASPN-830 (apomorphine infusion pump) NDA resubmission anticipated in the second half of 2021

ROCKVILLE, Md., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system... More